Literature DB >> 12042097

Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death.

Kenneth I Strauss1, Ann M Marini.   

Abstract

Primary insults to the brain can initiate glutamate release that may result in excitotoxicity followed by neuronal cell death. This secondary process is mediated by both N-methyl-D-aspartate (NMDA) and non-NMDA receptors in vivo and requires new gene expression. Neuronal cyclooxygenase-2 (COX2) expression is upregulated following brain insults, via glutamatergic and inflammatory mechanisms. The products of COX2 are bioactive prostanoids and reactive oxygen species that may play a role in neuronal survival. This study explores the role of neuronal COX2 in glutamate excitotoxicity using cultured cerebellar granule neurons (day 8 in vitro). Treatment with excitotoxic concentrations of glutamate or kainate transiently induced COX2 mRNA (two- and threefold at 6 h, respectively, p < 0.05, Dunnett) and prostaglandin production (five- and sixfold at 30 min, respectively, p < 0.05, Dunnett). COX2 induction peaked at toxic concentrations of these excitatory amino acids. Surprisingly, NMDA, L-quisqualate, and trans-ACPD did not induce COX2 mRNA at any concentration tested. The glutamate receptor antagonist NBQX (5 microM, AMPA/kainate receptor) completely inhibited kainate-induced COX2 mRNA and partially inhibited glutamate-induced COX2 (p < 0.05, Dunnett). Other glutamate receptor antagonists, such as MK-801 (1 microM, NMDA receptor) or MCPG (500 microM, class 1 metabotropic receptors), partially attenuated glutamate-induced COX2 mRNA. These antagonists all reduced steady-state COX2 mRNA (p < 0.05, Dunnett). To determine whether COX2 might be an effector of excitotoxic cell death, cerebellar granule cells were pretreated (24 h) with the COX2-specific enzyme inhibitor, DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2((5)H)-furanone) prior to glutamate challenge. DFU (1 to 1000 nM) completely protected cultured neurons from glutamate-mediated neurotoxicity. Approximately 50% protection from NMDA-mediated neurotoxicity, and no protection from kainate-mediated neurotoxicity was observed. Therefore, glutamate-mediated COX2 induction contributes to excitotoxic neuronal death. These results suggest that glutamate, NMDA, and kainate neurotoxicity involve distinct excitotoxic pathways, and that the glutamate and NMDA pathways may intersect at the level of COX2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042097      PMCID: PMC1456322          DOI: 10.1089/089771502753754091

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  59 in total

1.  Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture.

Authors:  S J Hewett; T F Uliasz; A S Vidwans; J A Hewett
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

2.  NMDA receptors and nitric oxide regulate prostaglandin D2 synthesis in the rabbit hippocampus in vivo.

Authors:  J W Łazarewicz; E Salińska; A Stafiej; A Ziembowicz; E Ziemińska
Journal:  Acta Neurobiol Exp (Wars)       Date:  2000       Impact factor: 1.579

Review 3.  Cyclooxygenases and the central nervous system.

Authors:  W E Kaufmann; K I Andreasson; P C Isakson; P F Worley
Journal:  Prostaglandins       Date:  1997-09

4.  Quantitative measurement of calretinin and beta-actin mRNA [correction of mRNAIN] in rat brain micropunches without prior isolation of RNA.

Authors:  K I Strauss; D M Jacobowitz
Journal:  Brain Res Mol Brain Res       Date:  1993-11

5.  Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat.

Authors:  K I Strauss; M F Barbe; R M Marshall; R Raghupathi; S Mehta; R K Narayan
Journal:  J Neurotrauma       Date:  2000-08       Impact factor: 5.269

6.  The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene.

Authors:  M Nagayama; K Niwa; T Nagayama; M E Ross; C Iadecola
Journal:  J Cereb Blood Flow Metab       Date:  1999-11       Impact factor: 6.200

7.  Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system.

Authors:  W D Hirst; K A Young; R Newton; V C Allport; D R Marriott; G P Wilkin
Journal:  Mol Cell Neurosci       Date:  1999-01       Impact factor: 4.314

8.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.

Authors:  D Panikashvili; C Simeonidou; S Ben-Shabat; L Hanus; A Breuer; R Mechoulam; E Shohami
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

9.  Glutamate receptor subtypes in cultured cerebellar neurons: modulation of glutamate and gamma-aminobutyric acid release.

Authors:  V Gallo; R Suergiu; C Giovannini; G Levi
Journal:  J Neurochem       Date:  1987-12       Impact factor: 5.372

10.  Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist.

Authors:  V L Marcheselli; N G Bazan
Journal:  J Biol Chem       Date:  1996-10-04       Impact factor: 5.157

View more
  24 in total

Review 1.  NSAIDs in the treatment and/or prevention of neurological disorders.

Authors:  Parto S Khansari; Leanne Coyne
Journal:  Inflammopharmacology       Date:  2012-01-10       Impact factor: 4.473

2.  Interaction of PGHS-2 and glutamatergic mechanisms controlling the ovine fetal hypothalamus-pituitary-adrenal axis.

Authors:  Nathan Knutson; Charles E Wood
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-05       Impact factor: 3.619

3.  Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury.

Authors:  Jonas J Gopez; Hongfei Yue; Ram Vasudevan; Amir S Malik; Lester N Fogelsanger; Shawn Lewis; David Panikashvili; Esther Shohami; Susan A Jansen; Raj K Narayan; Kenneth I Strauss
Journal:  Neurosurgery       Date:  2005-03       Impact factor: 4.654

4.  Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation.

Authors:  Juan Wang; Tao Pang; Roman Hafko; Julius Benicky; Enrique Sanchez-Lemus; Juan M Saavedra
Journal:  Neuropharmacology       Date:  2013-12-04       Impact factor: 5.250

Review 5.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

6.  Neuronal cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2 alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture.

Authors:  Wenjin Li; Shasha Wu; Robert W Hickey; Marie E Rose; Jun Chen; Steven H Graham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

7.  Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.

Authors:  Ava L Taylor; Joseph V Bonventre; Tracy F Uliasz; James A Hewett; Sandra J Hewett
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

8.  Platelet kainate receptor signaling promotes thrombosis by stimulating cyclooxygenase activation.

Authors:  Henry Sun; AnneMarie Swaim; Jesus Enrique Herrera; Diane Becker; Lewis Becker; Kalyan Srivastava; Laura E Thompson; Michelle R Shero; Alita Perez-Tamayo; Bhoom Suktitipat; Rasika Mathias; Anis Contractor; Nauder Faraday; Craig N Morrell
Journal:  Circ Res       Date:  2009-08-13       Impact factor: 17.367

9.  S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity.

Authors:  Jing Tian; Sangwon F Kim; Lynda Hester; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

10.  Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells.

Authors:  Anja-Kristina Brust; Holger K Ulbrich; Gail M Seigel; Norbert Pfeiffer; Franz H Grus
Journal:  Biomark Insights       Date:  2008-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.